TNNC2

Across TCGA pan-cancer cohorts, TNNC2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TNNC2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TNNC2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TNNC2 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where TNNC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TNNC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−1.787	<.001	8	view →
HNSC	Male	II,III,IV	−1.678	<.001	8	view →
LSCC	Male	All	−1.568	<.001	8	view →
OV	All	All	−1.084	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TNNC2–LUAD

Open the LUAD breakdown →